IMUC Key Stats
- 3 Stocks Under $10 Moving Higher The Street 03/07 03:00 ET
- ImmunoCellular Therapeutics to Report Financial Results for the Fourth Quarter and Full Year 2013 on March 13, 2014 PR Newswire 03/04 06:00 ET
- ImmunoCellular Therapeutics to Present at ROTH Conference on March 11th PR Newswire 03/03 06:00 ET
- Northwest Bio: Interim Analysis of Brain Cancer Vaccine Study Past Due The Street 03/03 05:32 ET
- Strength Seen in ImmunoCellular Therapeutics, Ltd. (IMUC): Stock Soars 14.05% - Tale of the Tape Zacks 02/26 02:44 ET
- Strength Seen in ImmunoCellular Therapeutics, Ltd. (IMUC): Stock Soars 14.05% Yahoo 02/26 02:23 ET
- IMMUNOCELLULAR THERAPEUTICS, LTD. Files SEC form 8-K, Other Events, Financial Statements and Exhibits Yahoo 02/25 11:59 ET
- ImmunoCellular (IMUC) Receives Orphan Drug Status for ICT-107 in Europe Street Insider 02/25 07:00 ET
- ImmunoCellular granted orphan drug designation for ICT-107 by EMA Yahoo 02/25 06:06 ET
- ImmunoCellular Therapeutics Receives Orphan Drug Status for ICT-107 in Glioblastoma in the European Union PR Newswire 02/25 06:00 ET
IMUC Total Returns Comparison
This total returns chart shows the returns to an investor from both price appreciation and dividends (dividends are assumed to be reinvested). ImmunoCellular Therapeuti is down 50.74% over the last year vs S&P 500 Total Return up 24.21%, Northwest Biotherapeutics up 50.75%, and Neostem up 21.94%.
Balance Sheet View Statement
Pro Ratings for IMUC
Pro Strategies Featuring IMUC
Did ImmunoCellular Therapeuti make it into our Pro Portfolio Strategies?
Start your YCharts Pro membership now to find out.
- Sector: Healthcare
- Industry: Biotechnology
- Headquarters Country: United States
- Headquarters State/Province: California
- Incorporation Country: United States
- Incorporation State/Province: Delaware
ImmunoCellular Therapeutics Limited is a clinical-stage biotechnology company that develops immune-based therapies for the treatment of cancers, such as brain, ovarian and other solid tumors.